Loteprednol Etabonate Suspension/ Drops
NDC 72485-665
Product Information
Loteprednol Etabonate is a ANDA-approved product labeled by Armas Pharmaceuticals Inc.. This medication is used to treat certain eye conditions due to inflammation or injury. It is supplied as a white suspension/ drops for ophthalmic administration. This product entry covers the primary NDC 72485-665 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 72485-665?
What are the uses of this product?
What are Active Ingredients of this product?
- LOTEPREDNOL ETABONATE 5 mg/mL - An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LOTEPREDNOL ETABONATE (UNII: YEH1EZ96K6)
- LOTEPREDNOL (UNII: Z8CBU6KR16) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- WATER (UNII: 059QF0KO0R)
- GLYCERIN (UNII: PDC6A3C0OX)
- TYLOXAPOL (UNII: Y27PUL9H56)
- EDETATE DISODIUM (UNII: 7FLD91C86K)
- POVIDONE K30 (UNII: U725QWY32X)
- BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 311382 - loteprednol etabonate 0.5 % Ophthalmic Suspension
- RxCUI: 311382 - loteprednol etabonate 5 MG/ML Ophthalmic Suspension
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.